



Progress towards the total synthesis of tedanolide: an efficient assembly of the C₁–C₁₁ subunit

Teck-Peng Loh* and Li-Chun Feng

Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543

Received 9 May 2001; revised 21 June 2001; accepted 28 June 2001

Abstract—The C₁–C₁₁ subunit of tedanolide was constructed using a boron-mediated *syn* aldol reaction as the key step to control the C₆ and C₇ stereocenters. Other features of this work include the asymmetric Sharpless dihydroxylation to incorporate the C₂, C₃ hydroxyl groups, selective protection of the hydroxyl group at C₂ as well as the usage of a *tert*-butyl ester to tolerate the attack of Grignard and enolate reagents. © 2001 Elsevier Science Ltd. All rights reserved.

Tedanolidide was isolated from a prevalent Caribbean sponge *Tedania ignis* by Schmitz and co-workers¹ in 1984. As a member of the macrolide group, tedanolide **1** shows very good biological activity as well as a very interesting chemical structure,^{1,2} which has initiated extensive synthetic studies towards its total synthesis.^{3–15} Recently, we have established an elegant and efficient construction of the C₁₃–C₂₃ fragment of tedanolide.³ In this article, we present our assembly of the C₁–C₁₁ subunit **4** of tedanolide.

As a synthetic target, tedanolide poses numerous challenges, including the assembly of two groups of crowded contiguous chiral centers (C₁₆ to C₁₉ and C₂ to

C₄) as well as the control of the stereochemistry of the C₆, C₇, C₁₆ and C₁₇ chiral centers. Retrosynthetically, tedanolide can be disconnected into two subunits **2** and **3** via disconnection at the C₂₉ lactone and the C₁₂, C₁₃ aldol unit, as outlined in Fig. 1. The subunit **2** was envisioned to derive from the intermediate **4**, which could be obtained from the coupling between precursors **5** and **6**. Precursor **6** can be easily synthesized according to the reported procedure.^{3,16} Our synthesis focuses on the preparation of the precursor **5**. As shown in Fig. 2, the precursor **5** can be traced back to the readily available aldehyde **9**. The key features of our strategy involve the *syn*–*syn* selective boron-mediated aldol reaction, as developed by Paterson,^{17,18} to




Figure 1.

* Corresponding author. Fax: (65)-7791691; e-mail: chmlhpt@nus.edu.sg




Figure 2.

control the C₆, C₇ stereochemistry, the asymmetric Sharpless dihydroxylation to incorporate the C₂, C₃ hydroxyl groups, selective protection of the hydroxyl group at C₂ as well as the use of a *tert*-butyl ester to tolerate the attack of Grignard and enolate reagents.


The synthesis of precursor **5** commenced with the preparation of the conjugated *tert*-butyl ester **7**, which was easily obtained as a single isomer in 83% yield via a Wittig reaction of aldehyde **9** with the stabilized Wittig reagent *t*-BuO₂CCH=PPh₃.^{19–21} Next, Sharpless asymmetric dihydroxylation using AD-mix- α was explored to incorporate the C₂, C₃ hydroxyl groups (Scheme 1).^{10,22,23}

It can be seen from the results that the expected diol **8** was obtained in excellent yield with very good selectivity (86:14) when AD-mix- α was employed. The two diastereoisomers can be easily separated by flash silica gel column chromatography. The stereochemistry of the desired *syn* dihydroxylation product was established as shown in Scheme 2 by analysis of the coupling constant between the protons H₃ and H₄ of the acetal **11** (a mixture of two isomers, ratio: 77:23), which was prepared from diol **8** through selective protection of the vicinal diol²⁴ and acetal formation mediated by DDQ.


The formation of acetal **11** confirmed the selective protection of the hydroxyl group at C₂.

Having successfully incorporated the C₂ and C₃ chiral centers, we carried on with the synthesis of precursor **5** from **10**, starting with the methyl protection of the hydroxyl group. Due to the crowded environment around the hydroxyl group, strong reaction conditions (Ag₂O, MeI, CH₃CN, reflux) were employed. However, this led to the cleavage of the TBDPS protecting group and none of the desired product. In order to circumvent this, TBDMS was introduced as a protecting group and alternative methylation conditions^{25,26} were explored (Scheme 3). From these conditions, AgOTf/MeI²⁶ was found to be more desirable, providing the expected product **13** in 50% yield.


Further elaboration of precursor **5** began with the removal of the PMB protecting group of the *tert*-butyl ester **13** (Scheme 4). Treatment of **13** with DDQ (1.1 equiv.) provided the alcohol **14** cleanly in 85% yield. Dess–Martin oxidation of alcohol **14** afforded aldehyde **15** in excellent yield (97%). Grignard reaction of aldehyde **15** with ethylmagnesium bromide was then successfully carried out in Et₂O at –78°C to give the desired alcohol **16**, which was subjected to another



Scheme 1.



Scheme 2.



Scheme 6.

Besides, a *tert*-butyl ester was employed to tolerate the attack of Grignard and enolate reagents. The assembly of subunit **2** and its combination with subunit **3** are in progress.

Acknowledgements

This work was financially supported by grants from the National University of Singapore.

References

- Schmitz, F. J.; Gunasekera, S. P.; Yalamanchili, G.; Hossain, M. B.; Van der Helm, D. *J. Am. Chem. Soc.* **1984**, *106*, 7251.
- Schmitz, F. J.; Gunasekera, S. P.; Hossain, M. B.; Van der Helm, D.; Yalamanchili, G. U. S. Patent Application 87-7347 870127.
- Loh, T. P.; Feng, L. C. *Tetrahedron Lett.* **2000**, *42*, 3223.
- Matsushima, T.; Horita, K.; Nakajima, N.; Yonemitsu, O. *Tetrahedron Lett.* **1996**, *37*, 385.
- Matsushima, T.; Mori, M.; Nakajima, N.; Maeda, H.; Uenishi, J.; Yonemitsu, O. *Chem. Pharm. Bull.* **1998**, *46*, 1335.
- Liu, J. F.; Abiko, A.; Pei, Z.-H.; Buske, D. C.; Masamune, S. *Tetrahedron Lett.* **1998**, *39*, 1873.
- Taylor, R. E.; Ciavarrri, J. P.; Hearn, B. R. *Tetrahedron Lett.* **1998**, *39*, 9361.
- Matsushima, T.; Mori, M.; Zheng, B. Z.; Maeda, H.; Nakajima, N.; Uenishi, J.; Yonemitsu, O. *Chem. Pharm. Bull.* **1999**, *47*, 308.
- Zheng, B. Z.; Maeda, H.; Mori, M.; Kusaka, S.; Yonemitsu, O.; Matsushima, T.; Nakajima, N.; Uenishi, J. *Chem. Pharm. Bull.* **1999**, *47*, 1288.
- Matsushima, T.; Zheng, B. Z.; Maeda, H.; Nakajima, N.; Uenishi, J.; Yonemitsu, O. *Synlett* **1999**, 780.
- Roush, W. R.; Lane, G. C. *Org. Lett.* **1999**, *1*, 95.
- Smith, A. B., Lodise, S. *Papers*, 218th National Meeting of the American Chemical Society, New Orleans, LA, Aug. 22–26, 1999; American Chemical Society: Washington, DC, 1999; p. 549; *Org. Lett.* **1999**, *1*, 1249.
- Jung, M. E.; Marquez, R. *Org. Lett.* **2000**, *2*, 1669.
- Jung, M. E.; Lee, C. P. *Tetrahedron Lett.* **2000**, *41*, 9719.
- Jung, M. E.; Lee, C. P. *Org. Lett.* **2001**, *3*, 333.
- Paterson, I.; Tillyer, R. D. *J. Org. Chem.* **1993**, *58*, 4182.
- Paterson, I.; McClure, C. K. *Tetrahedron Lett.* **1987**, *28*, 1229.
- Paterson, I.; Hulme, A. N. *J. Org. Chem.* **1995**, *60*, 3288.
- Tomooka, K.; Kikuchi, M.; Igawa, K.; Suzuki, M.; Keong, P. H.; Nakai, T. *Angew. Chem., Int. Ed.* **2000**, *39*, 4502.
- Paterson, I.; Boddy, I.; Mason, I. *Tetrahedron Lett.* **1987**, *28*, 5205.
- Harris, C. R.; Kuduk, S. D.; Balog, A.; Savin, K.; Glunz, P. W.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1999**, *121*, 7050.
- Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K. S.; Kwong, H. L.; Morikawa, K.; Wang, Z. M.; Xu, D.; Zhang, X. L. *J. Org. Chem.* **1992**, *57*, 2768.
- Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.* **1994**, *94*, 2483.
- Bhatt, R. K.; Chauhan, K.; Wheelan, P.; Murphy, R. C.; Falck, J. R. *J. Am. Chem. Soc.* **1994**, *116*, 5050.
- Greene, A. E.; Drian, C. L.; Crabbe, P. *J. Am. Chem. Soc.* **1980**, *102*, 7583.
- Burk, R. M.; Gac, T. S.; Roof, M. B. *Tetrahedron Lett.* **1994**, *35*, 8111.
- Brown, H. C.; Rogic, M. M.; Rathke, M. W.; Kabalka, G. W. *ibid.* **1968**, *90*, 818.
- Mukaiyama, T.; Inoue, T. *Chem. Lett.* **1976**, 559.
- Inoue, T.; Mukaiyama, T. *Bull. Chem. Soc. Jpn.* **1980**, *53*, 174.
- Masammune, S.; Mori, S.; Van Horn, D.; Brooks, D. W. *Tetrahedron Lett.* **1979**, 1665.

31. Evans, D. A.; Nelson, J. V.; Vogel, E.; Taber, T. R. *J. Am. Chem. Soc.* **1981**, *103*, 3099.
32. Chen, K. M.; Hardtmann, G. E.; Prasad, K.; Repic, O.; Shapiro, M. J. *Tetrahedron Lett.* **1987**, *28*, 155.
33. Bernardi, A.; Capelli, A. M.; Comotti, A.; Gennari, C.; Gardner, M.; Goodman, J. M.; Paterson, I. *Tetrahedron* **1991**, *47*, 3471. Data for compound **4**: R_f 0.86 (*n*-hexane/EtOAc, 4:1); $[\alpha]_D^{29} + 19$ (*c* 0.3, ethyl acetate); ^1H NMR (300 MHz, CDCl_3) δ (ppm): 7.62–7.59 (m, 4H, Ph), 7.34–7.27 (m, 6H, Ph), 5.24 (d, $J=9.4$ Hz, 1H, =CH), 4.09 (d, $J=8.0$ Hz, 1H, CHOTBS), 4.08 (br, 1H, =CCHO), 3.68 (dd, $J=1.4, 9.4$ Hz, 1H, CHO), 3.46 (s, 3H, OMe), 3.47 (dd, $J=6.0, 9.4$ Hz, 1H, CH_2OTBDPS), 3.39 (dd, $J=7.3, 9.4$ Hz, 1H, CH_2OTBDPS), 3.29 (dd, $J=1.2, 8.0$ Hz, 1H, CHOMe), 2.64–2.54 (m, 1H, CHCH_3), 1.68–1.60 (m, 1H, CHCH_3), 1.43–1.33 (m, 1H, CHCH_3), 1.42 (s, 3H, =CCH₃), 1.39 (s, 9H, *t*-BuO), 1.32 (s, 3H, CCH₃), 1.31 (s, 3H, CCH₃), 0.97 (s, 9H, *t*-BuSi(Ph)₂), 0.95 (d, $J=6.6$ Hz, 3H, CHCH_3), 0.89 (d, $J=6.6$ Hz, 3H, CHCH_3), 0.85 (s, 9H, *t*-BuSi(Me)₂), 0.58 (d, $J=6.6$ Hz, 3H, CHCH_3), 0.04 (s, 3H, CH_3Si), 0.02 (s, 3H, CH_3Si); ^{13}C NMR (75.4 MHz, CDCl_3) δ (ppm): 170.8, 135.6 (2), 134.1, 132.3, 129.4, 127.5, 127.1, 98.8, 81.4, 81.3, 75.7, 74.9, 68.5, 61.4, 55.5, 36.4, 35.0, 31.9, 30.0, 27.8, 26.8, 25.7, 19.5, 19.2, 18.1, 17.5, 13.6, 9.7, 4.9, –5.0 (2); IR (neat, KBr plate) cm^{-1} : 3072, 3051, 2960, 2931, 2858, 1739, 1463, 1428, 1368, 1256, 1113, 1008, 838, 780, 758, 703, 505; HRMS (ESI) calcd for $\text{C}_{45}\text{H}_{74}\text{O}_7\text{Si}_2\text{Na}$ $[\text{M}+\text{Na}^+]$: 805.4873; Found: 805.4874.